Search

Your search keyword '"Song, Xingzhi"' showing total 477 results

Search Constraints

Start Over You searched for: Author "Song, Xingzhi" Remove constraint Author: "Song, Xingzhi"
477 results on '"Song, Xingzhi"'

Search Results

1. Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.

2. Author Correction: Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

6. Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia

7. T-prolymphocytic leukemia: TCL1 or MTCP1 rearrangement is not mandatory to establish diagnosis

8. Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma

9. Proteogenomic landscape of gastric adenocarcinoma peritoneal metastases

10. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease

11. Mechanisms of nuclear content loading to exosomes.

13. Clonal evolution of hematopoietic stem cells after cancer chemotherapy

14. Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor

15. Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma

16. Metagenomes of rectal swabs in larger, advanced stage cervical cancers have enhanced mucus degrading functionalities and distinct taxonomic structure

17. Multi-modal molecular programs regulate melanoma cell state

18. Epstein Barr virus–positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo

19. Supplementary Table 6 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

20. Supplementary Figure 6 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

21. Supplementary Figure 8 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

22. Supplementary Table 3 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

23. Supplementary Figure 1 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

24. Supplementary Table 1 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

25. Supplementary Figure 7 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

26. Data from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

27. Supplementary Figure 2 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

28. Supplementary Table 7 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

29. Supplementary Table 4 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

30. Supplementary Figure 5 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

31. Supplementary Table 2 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

32. Supplementary Figure 3 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

33. Supplementary Figure 4 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

34. Supplementary Table 5 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

35. Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform

36. Supplementary File 1 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity

37. Supplementary Figures S1-S28 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity

38. Data from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity

39. Supplementary Tables 1-8 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity

40. Supplementary File 2 from Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity

41. Intratumoral Microbiome of Adenoid Cystic Carcinomas and Comparison with Other Head and Neck Cancers

42. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma

43. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

44. Abstract A029: DDR pathway genes in CRT resistance: Insights from longitudinal whole exome sequencing in cervical cancer

45. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

46. Author Correction: Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma

47. Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

48. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer

49. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

50. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics

Catalog

Books, media, physical & digital resources